FDA Warning Letter

Regulatory Event

On June 2, 2026, FDA issued Warning Letter 320-26-87 to Laboratorios Dr. Collado S.A., an over-the-counter drug manufacturer at Parque Industrial Duarte Km 22 1/2, Autopista Duarte, Santo Domingo Norte, Dominican Republic. The letter cites two systemic violations: a failure to establish laboratory controls with scientifically sound specifications and test procedures under 21 CFR 211.160(b), and a failure of the quality unit to exercise its oversight responsibilities under 21 CFR 211.22. The product is a talc-containing OTC drug product, and the specific deficiencies include the absence of an asbestos testing specification, use of an analytically inadequate SEM protocol at a contract laboratory, and unvalidated test methods. The company has committed to cease manufacturing drug products containing talc.

What makes this Warning Letter instructive for quality directors managing OTC drug programs is the structural completeness of the failure: a manufacturer that accepted talc components into production without a written specification for the absence of asbestos, contracted out the analytical testing without adequate method oversight, and allowed a quality unit to release components without confirming that the test procedures met basic scientific fitness-for-purpose standards. Together, these represent a complete breakdown in what 21 CFR 211.160(b) requires — specifications, sampling plans, and test procedures designed as an integrated system to assure that drug components conform to appropriate standards of identity, strength, quality, and purity before entering the manufacturing process.

The specification gap is the foundational failure. FDA’s finding states that the firm’s specifications for talc components did not include testing for assay and multiple impurities, and — most critically — lacked any specification requiring testing for the absence of asbestos. The current USP (United States Pharmacopeia) talc monograph includes a specific test for asbestos absence, and FDA’s letter notes the monograph has been recently revised with updated technical requirements for such testing, scheduled to become official. Under section 501(b) of the FD&C Act, drugs — including components recognized in the USP — are generally required to meet the current applicable USP monograph. A specification that does not incorporate those requirements is, by definition, incomplete under 21 CFR 211.160(b). The standard is not aspirational; it is the floor. For any OTC manufacturer, specification completeness requires active monitoring of USP monograph revisions, particularly when the monograph covers a component with a documented safety risk profile.

What the Record Documents

The SEM methodology finding carries equal analytical weight. Laboratorios Dr. Collado used a contract testing laboratory for asbestos testing by scanning electron microscopy, and the SEM data submitted to FDA showed magnification levels that were, in the agency’s words, “inadequate to determine the morphology of individual particles in the talc or to reliably detect and characterize potential asbestos.” Asbestos fibers — chrysotile, tremolite, actinolite — have aspect ratios and size distributions that require sufficient SEM magnification to differentiate fiber morphology from non-fibrous cleavage fragments. Industry practice, consistent with the updated USP talc monograph, calls for SEM magnification capable of resolving individual fiber morphology at the sub-micron scale. Submitting magnification data that cannot perform this function means the testing program, however consistently executed, cannot generate the data needed to make a valid release or rejection decision. This violates both 21 CFR 211.160(b) and the foundational principle that methods must be validated to show suitability for their intended use — a requirement codified in International Council for Harmonisation (ICH) Q2(R2) and USP <1225>.

The enforcement logic parallels the framework established in FDA v. Barr Laboratories, Inc. (D.N.J. 1993) and applied in Mylan Pharmaceuticals’ 2011 Warning Letter from its Morgantown, West Virginia facility: a manufacturer cannot make a scientifically defensible quality determination using an analytical method that has not been demonstrated fit for purpose. In the Collado case, the contract laboratory’s asbestos test reports were accepted as evidence of conformance without the quality unit verifying that the underlying method could actually detect what it was supposed to detect. The label on the test report is not the standard; the scientific capability of the method is.

Technical and Quality Context

The quality unit finding under 21 CFR 211.22 is the governance failure that allowed the above to persist. FDA states the QU failed to review or approve test methods and specifications for asbestos testing in talc, failed to oversee the contract laboratory to ensure it used a scientifically sound and fit-for-purpose method, and approved and accepted talc for use in drug manufacturing without ensuring CGMP (Current Good Manufacturing Practice) compliance. Under 21 CFR 211.22, the QU holds independent approval authority over all specifications and test procedures that affect product identity, strength, quality, and purity. That authority cannot be delegated to a contract laboratory by issuing a purchase order for testing. As FDA’s letter states, it regards contractors as extensions of the manufacturer. A QU that accepts a certificate of analysis without independently verifying the adequacy of the method by which that COA was generated has not exercised its authority — it has abdicated it.

The remediation path requires three concurrent actions: specifications rebuilt against current USP monograph requirements with a documented gap analysis for all active and inactive components; analytical methods validated for fitness-for-purpose before any further use in component qualification decisions — for talc asbestos testing, this means demonstrating that SEM magnification and fiber identification criteria can detect asbestos at levels required by the revised USP monograph; and a quality unit oversight structure rebuilt to include explicit review and approval of all contract laboratory methods before those methods generate data that supports release decisions.

Decision Relevance

The broader enforcement signal from CDER’s Office of Manufacturing Quality is consistent with FDA’s stated priority on higher-risk OTC drug categories. A talc-containing drug product applicable to body areas with inhalation or dermal exposure risk — lacking a validated asbestos absence test — is precisely the risk profile FDA’s OTC oversight framework targets. The warning about potential import detention under section 801(a)(3) of the FD&C Act reflects the agency’s enforcement posture for firms that cannot demonstrate their manufacturing controls conform to CGMP. For quality directors at international OTC manufacturing sites, the message is direct: a specification that does not cover known safety-relevant impurities, paired with an analytical method that cannot detect those impurities, is not a defensible laboratory controls program regardless of how long it has been in place.

At XGene Consulting, we work with OTC and NDA (New Drug Application)-stage manufacturers on laboratory controls remediation: building specifications from USP monograph requirements, conducting method fitness-for-purpose assessments under ICH Q2(R2), and establishing quality unit oversight protocols that treat contractor methods as subject to the same review and approval as internal procedures. The Collado Warning Letter is not a talc story. It is a story about what happens when specification completeness, method validation, and quality unit authority are treated as separate administrative tasks rather than as one integrated laboratory control system. If you are managing a talc-containing OTC drug portfolio, a mineral-derived component qualification program, or a contract laboratory oversight structure that has not been audited against 21 CFR 211.160(b) and 211.22 requirements, connect with me at xgeneconsulting.com or via LinkedIn.